

FORM 5

QUARTERLY LISTING STATEMENT

Name of Listed Issuer: Sona Nanotech Inc. (the "Issuer").

Trading Symbol: SONA

This Quarterly Listing Statement must be posted on or before the day on which the Issuer's unaudited interim financial statements are to be filed under the *Securities Act*, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer's first, second and third fiscal quarters. This statement is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website.

SCHEDULE A: FINANCIAL STATEMENTS

Financial statements are required as follows:

For the first, second and third financial quarters interim financial statements prepared in accordance with the requirements under Ontario securities law must be attached.

If the Issuer is exempt from filing certain interim financial statements, give the date of the exempting order.

See the Issuer's financial statements for the period ended April 30, 2020, also filed on the CSE website as at today's date.

SCHEDULE B: SUPPLEMENTARY INFORMATION

The supplementary information set out below must be provided when not included in Schedule A.

1. Related party transactions

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

- (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as

affiliate, associate or related company without further clarifying details are not sufficient.

- (b) A description of the transaction(s), including those for which no amount has been recorded.
- (c) The recorded amount of the transactions classified by financial statement category.
- (d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
- (e) Contractual obligations with Related Persons, separate from other contractual obligations.
- (f) Contingencies involving Related Persons, separate from other contingencies.

All related party transactions have been disclosed in the notes 15 and 19 of the Issuer's financial statements for the period ended April 30, 2020, also filed on the CSE website as at today's date. Refer also to the Issuer's Management's Discussion and Analysis for the period ended April 30, 2020, also filed on the CSE website as at today's date.

2. Summary of securities issued and options granted during the period.

Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A):

- (a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid
July 16, 2019	Common shares	Debt conversion	4,067,489	\$0.25	1,027,847	Debt settlement	Note 12 Year ended Oct. 31, 2019	n/a
June 4, 2019	Common shares	Exercise of options	206,250	\$0.20	59,710	cash	Note 13 Year ended Oct. 31, 2019	n/a
Jan 13, 2020	Common shares	Note conversion	2,520,270	\$0.20	543,775	Note settlement	Notes 10 & 19 Qtr. ended Jan 31, 2020	n/a
April 3, 2020	Common shares	Exercise of options	127,500	\$0.20	25,500	cash	Note 10 Qtr ended April 30, 2020	n/a
April 19, 2020	Common shares	Exercise of warrants	400,000	\$0.25	100,000	cash	Note 10 Qtr ended April 30, 2020	n/a

(b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant
Jan 21, 2019	1,410,000	Various – See Option Issuance Summary CSE Form 11	Same	\$0.35	Jan 21, 2024	\$0.35
March 17, 2020	1,100,000	Various – See Option Issuance Summary CSE Form 11	Same	\$0.60	March 17, 2025	\$0.60

3. Summary of securities as at the end of the reporting period.

Provide the following information in tabular format as at the end of the reporting period:

- (a) description of authorized share capital including number of shares for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,
- (b) number and recorded value for shares issued and outstanding,
- (c) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and
- (d) number of shares in each class of shares subject to escrow or pooling agreements or any other restriction on transfer.

A summary of securities is included in note 10 and the Statement of Changes in Equity in the Issuer's financial statements for the period ended April 30, 2020 also filed on the CSE website as at today's date.

List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.

Name	Position(s) held
Darren Rowles	Chief Executive Officer and President
Rob Randall	Chief Financial Officer and Corporate Secretary
Michael Gross	Director
Zephania Mbgua	Director
Jim Megann	Director
Robert McKay	Director
Dan Whittaker	Director

SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS

Provide Interim MD&A if required by applicable securities legislation.

See the Issuer's management discussion and analysis of financial condition and results of operations for the period ended April 30, 2020, also filed on the CSE website as at today's date.

.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated June 29, 2020

Rob Randall
Name of Director or Senior Officer

"Rob Randall"
Signature

CFO & Corporate Secretary
Official Capacity

Issuer Details Name of Issuer Sona Nanotech Inc.	For Quarter Ended April 30, 2020	Date of Report YY/MM/D 20/06/29
Issuer Address 1 Research Drive, Bay 2, Dartmouth, Nova Scotia, B2Y 4M9 Suite 2001, 1969 Upper Water Street, Halifax, Nova Scotia, B3J 3R7		
City/Province/Postal Code Halifax, Nova Scotia B3J 3R7	Issuer Fax No. (902) 491-4281	Issuer Telephone No. (902) 442-0653
Contact Name Darren Rowles	Contact Position President & CEO	Contact Telephone No. (902) 442-0653
Contact Email Address darren@sonanano.com	Web Site Address www.sonananocom	